非小細胞肺がん(Non-Small Cell Lung Carcinoma):治療薬開発パイプライン動向2018

【英語タイトル】Non-Small Cell Lung Carcinoma-Pipeline Insights, 2018

DelveInsightが出版した調査資料(DIPR2016455)・商品コード:DIPR2016455
・発行会社(調査会社):DelveInsight
・発行日:2018年11月
・ページ数:約60
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後3営業日)
・調査対象地域:グローバル
・産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名使用)USD1,250 ⇒換算¥141,250見積依頼/購入/質問フォーム
Site Price(同一国内共有可)USD2,500 ⇒換算¥282,500見積依頼/購入/質問フォーム
Enterprise Price(複数国内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日~2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
※本調査レポートでは、世界における非小細胞肺がん(Non-Small Cell Lung Carcinoma)の治療薬開発パイプライン動向について調査・分析し、企業別開発中の治療薬、各臨床試験段階における製品リスト及び比較分析、薬剤候補のプロファイル、治療薬の評価、開発中止又は開発休止中の薬剤リスト等をお届けしています。また、非小細胞肺がん(Non-Small Cell Lung Carcinoma)治療薬開発に取り組んでいる企業情報も提供しています。

・非小細胞肺がん(Non-Small Cell Lung Carcinoma)の概要

・非小細胞肺がん(Non-Small Cell Lung Carcinoma)の治療薬パイプライン概要

・企業別開発中の非小細胞肺がん(Non-Small Cell Lung Carcinoma)治療薬

・後期治験段階の薬剤(Filed & Phase III):比較分析

・中期治験段階の薬剤(Phase II):比較分析

・初期治験段階の薬剤(Phase I & IND Filed):比較分析

・前臨床段階の薬剤:比較分析

・薬剤候補のプロファイル

・非小細胞肺がん(Non-Small Cell Lung Carcinoma)治療薬の評価
  - 単剤治療薬別評価
  - 併用治療薬別評価
  - 投与経路別評価
  - 分子種類別評価

・開発が中止された薬剤リスト

・開発休止中の薬剤リスト

・非小細胞肺がん(Non-Small Cell Lung Carcinoma)治療薬開発に取り組んでいる企業リスト

・図表一覧
【レポートの概要】

SUMMARY
DelveInsight’s, “ Non-Small Cell Lung Carcinoma-Pipeline Insights, 2018”, report provides in depth insights on the pipeline drugs and their development activities around the Non-Small Cell Lung Carcinoma. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Non-Small Cell Lung Carcinoma. DelveInsight’s Report also assesses the Non-Small Cell Lung Carcinoma therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.


Scope
• The report provides competitivepipeline landscape of Non-Small Cell Lung Carcinoma
• The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
• Coverage of the Non-Small Cell Lung Carcinoma pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
• The report reviews key players involved in the therapeutics development for Non-Small Cell Lung Carcinoma and also provide company profiling
• The report also gives the information of dormant and discontinued pipeline projects
• Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type


【レポートの目次】

Table of Contents
• Non-Small Cell Lung Carcinoma Overview
• Non-Small Cell Lung Carcinoma Pipeline Therapeutics
• Non-Small Cell Lung Carcinoma Therapeutics under Development by Companies
• Non-Small Cell Lung Carcinoma Filed and Phase III Products
• Comparative Analysis
• Non-Small Cell Lung Carcinoma Phase II Products
• Comparative Analysis
• Non-Small Cell Lung Carcinoma Phase I and IND Filed Products
• Comparative Analysis
• Non-Small Cell Lung Carcinoma Discovery and Pre-Clinical Stage Products
• Comparative Analysis
• Drug Candidate Profiles
• Non-Small Cell Lung Carcinoma – Therapeutics Assessment
• Assessment by Monotherapy Products
• Assessment by Combination Products
• Assessment by Route of Administration
• Assessment by Molecule Type
• Non-Small Cell Lung Carcinoma – Discontinued Products
• Non-Small Cell Lung Carcinoma – Dormant Products
• Companies Involved in Therapeutics Development for Non-Small Cell Lung Carcinoma
• Appendix
• Methodology
• Contact Us
• Disclaimer

List of Tables
• Number of Products under Development for Non-Small Cell Lung Carcinoma, 2018
• Number of Products under Development by Companies
• Comparative Analysis by Filed and Phase III Products, 2018
• Comparative Analysis Phase II Products, 2018
• Comparative Analysis Phase I and IND Filed Products, 2018
• Comparative Analysis Discovery and Pre-Clinical Stage Products, 2018
• Drug Candidates Profiles
• Non-Small Cell Lung Carcinoma Assessment by Monotherapy Products
• Non-Small Cell Lung Carcinoma Assessment by Combination Products
• Non-Small Cell Lung Carcinoma Assessment by Route of Administration
• Non-Small Cell Lung Carcinoma Assessment by Stage and Route of Administration
• Non-Small Cell Lung Carcinoma Assessment by Molecule Type
• Non-Small Cell Lung Carcinoma Assessment by Stage and Molecule Type
• Non-Small Cell Lung Carcinoma Therapeutics – Discontinued Products
• Non-Small Cell Lung Carcinoma Therapeutics – Dormant Products
• Products under Development by Companies, 2018


List of Figures
• Number of Products under Development for Non-Small Cell Lung Carcinoma, 2018
• Filed and Phase III Products, 2018
• Phase II Products, 2018
• Phase I and IND Filed Products, 2018
• Discovery and Pre-Clinical Stage Products, 2018
• Non-Small Cell Lung Carcinoma Assessment by Monotherapy Products
• Non-Small Cell Lung Carcinoma Assessment by Combination Products
• Non-Small Cell Lung Carcinoma Assessment by Route of Administration
• Non-Small Cell Lung Carcinoma Assessment by Stage and Route of Administration
• Non-Small Cell Lung Carcinoma Assessment by Molecule Type
• Non-Small Cell Lung Carcinoma Assessment by Stage and Molecule Type


【レポートのキーワード】

非小細胞肺がん(Non-Small Cell Lung Carcinoma)、治療薬、医薬品、薬剤、製薬企業、研究開発、治験、パイプライン

★調査レポート[非小細胞肺がん(Non-Small Cell Lung Carcinoma):治療薬開発パイプライン動向2018] (コード:DIPR2016455)販売に関する免責事項を必ずご確認ください。
★調査レポート[非小細胞肺がん(Non-Small Cell Lung Carcinoma):治療薬開発パイプライン動向2018]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆